SCOPE 2019

Not there yet? With bad data, AI accelerates bad processes: SCOPE panelist

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/kishore kumar)
(Image: Getty/kishore kumar)

Related tags: Artificial intelligence, AI

Artificial intelligence works best in a standardized environment, say industry experts. Workflows and processes must first be aligned to successfully use the technology – is pharma ready?

“AI is very sexy … And it sounds really good and it's going to be helpful and solve these issues for you. But the reality is about 70% of AI products fail,” ​said Ron Williams, CEO of Business Evolution, during a panel discussion at the SCOPE Summit last week.

Why do so many products fail? Because they start with AI, he said. “And you can’t start with AI; AI is the last step of the process.”

The first step is fixing workflows, said Williams, “If our workflow is broken and we don’t fix it, not only are we moving bad data into AI, we’re going to accelerate the bad process.”

Combining bad data with bad processes is going to yield a “disappointing result,”​ he added. And the successful implementation of the technology is going to be a long road – and as Williams said, AI is not the panacea.

“Breaking down the thought process is the first change that will allow innovation to be leveraged,”​ he added, calling the industry’s behavior “very consistent with the old way of thinking.”

“I need you to engage a different thought process and different framework,”​ said Williams, providing insight from outside the industry.

Offering his thoughts as the head of clinical trial analytics at Bristol-Myers Squibb, Balazs Flink, MD, said that while pharma likes to think it is unique – it is “unique in the way that every other industry is unique.”

Flink said, “We have to constantly challenge ourselves,”​ to meet the need of patients and providers amid a rapidly changing value framework.

Still, the challenge of successfully using AI is not to be diminished. “AI works best in a relatively standardized, stable environment,”​ said Flink. “We are not there yet.”

Related topics: Clinical Development, Data management

Related news

Show more

Related products

show more

Efficient Clinical Supply Management & Forecasting

Efficient Clinical Supply Management & Forecasting

Catalent Pharma Solutions | 30-Nov-2021 | Insight Guide

How can clinical supply management benefit your trials? Download this eBook to explore how you can drive excellence within the forecasting process, as...

Paper vs ePRO Data Collection Methods

Paper vs ePRO Data Collection Methods

Signant Health | 19-Oct-2021 | Technical / White Paper

Are you curious why more Sponsors choose digital data collection methods over the traditional pen and paper? Read this recent white paper to discover the...

Related suppliers

Follow us


View more